Daniel Stetson

4.3k total citations · 2 hit papers
27 papers, 2.2k citations indexed

About

Daniel Stetson is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Daniel Stetson has authored 27 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Daniel Stetson's work include Cancer Genomics and Diagnostics (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Molecular Biology Techniques and Applications (4 papers). Daniel Stetson is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Molecular Biology Techniques and Applications (4 papers). Daniel Stetson collaborates with scholars based in United States, United Kingdom and South Korea. Daniel Stetson's co-authors include J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne, Brian Dougherty, Cloud P. Paweletz, Byoung Chul Cho, Zhongwu Lai, Aleksandra Markovets, Enriqueta Felip and Dalia Ercan and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Daniel Stetson

27 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. Nature Medicine profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations James Chih‐Hsin Yang, Helen Mann et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Stetson United States	11	1.4k	1.1k	1.0k	724	198	27	2.2k
Raymond Pagliarini United States	16	168 0.1×	543 0.5×	1.6k 1.6×	525 0.7×	106 0.5×	20	2.3k
Elena Pagani Italy	17	143 0.1×	648 0.6×	1.1k 1.1×	450 0.6×	233 1.2×	34	1.6k
Brian Higgins United States	14	436 0.3×	444 0.4×	1.2k 1.2×	198 0.3×	41 0.2×	26	1.6k
Rocı́o Sotillo Germany	23	407 0.3×	1.7k 1.5×	2.6k 2.5×	686 0.9×	151 0.8×	40	3.7k
Raphaël Ceccaldi France	17	198 0.1×	1.9k 1.7×	3.5k 3.4×	576 0.8×	163 0.8×	22	4.3k
Robert McEwen United Kingdom	20	495 0.4×	613 0.5×	1.1k 1.1×	651 0.9×	230 1.2×	37	2.2k
Meghna Das Thakur United States	14	234 0.2×	580 0.5×	820 0.8×	260 0.4×	118 0.6×	28	1.3k
Kristen E. Mengwasser United States	7	1.1k 0.8×	1.1k 1.0×	1.5k 1.5×	523 0.7×	147 0.7×	8	2.4k
Katrien Berns Netherlands	15	343 0.2×	1.2k 1.1×	2.2k 2.1×	537 0.7×	213 1.1×	19	3.0k
Ying C. Henderson United States	25	236 0.2×	1.0k 0.9×	1.3k 1.2×	509 0.7×	131 0.7×	39	2.4k

Countries citing papers authored by Daniel Stetson

Since Specialization

Citations

This map shows the geographic impact of Daniel Stetson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Stetson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Stetson more than expected).

Fields of papers citing papers by Daniel Stetson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Stetson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Stetson. The network helps show where Daniel Stetson may publish in the future.

Co-authorship network of co-authors of Daniel Stetson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Stetson. A scholar is included among the top collaborators of Daniel Stetson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Stetson. Daniel Stetson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baden, Jonathan, Mark Sausen, Andrew Anfora, et al.. (2025). Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays. Journal of Molecular Diagnostics. 27(10). 914–919. 1 indexed citations

Stetson, Daniel, David Shera, Chris Abbosh, et al.. (2024). Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?. Journal of Clinical Oncology. 42(23). 2736–2740. 10 indexed citations

Roschewski, Mark, Manish R. Patel, Patrick M. Reagan, et al.. (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical Cancer Research. 29(17). 3301–3312. 13 indexed citations

Willaredt, Marc A., Daniel Stetson, Joachim Kirsch, et al.. (2023). Primary cilia are critical for tracheoesophageal septation. Developmental Dynamics. 253(3). 312–332. 4 indexed citations

Stetson, Daniel, Gregory T. Jones, Giovanni Marsico, et al.. (2023). Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Cancer Research. 83(7_Supplement). 3384–3384. 1 indexed citations

Abbosh, Chris, Michael Kuziora, Daniel Stetson, et al.. (2023). Abstract 2299: Misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial. Cancer Research. 83(7_Supplement). 2299–2299. 3 indexed citations

Lipsyc-Sharf, Marla, Elza C. de Bruin, Robert McEwen, et al.. (2022). Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 40(22). 2408–2419. 85 indexed citations

Lim, Sun Min, Sangbin Lim, Seong Gu Heo, et al.. (2022). Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic Advances in Medical Oncology. 14. 4287491157–4287491157. 14 indexed citations

Lipsyc-Sharf, Marla, Elza de Bruin, Robert McEwen, et al.. (2022). Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).. Journal of Clinical Oncology. 40(16_suppl). 103–103. 6 indexed citations

10.

Williams, P. Mickey, Steven P. Lund, Kenneth D. Cole, et al.. (2021). Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO Precision Oncology. 5(5). 910–920. 14 indexed citations

11.

Hsu, Chia‐Chi, Bin-Chi Liao, Wei‐Yu Liao, et al.. (2019). Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 15(1). 50–61. 61 indexed citations

12.

Stetson, Daniel, Ambar Ahmed, Xing Xu, et al.. (2019). Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. JCO Precision Oncology. 3(3). 1–9. 112 indexed citations

13.

Hollis, Robert L., Alison Meynert, Michael Churchman, et al.. (2019). Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas. 749–749. 1 indexed citations

14.

Hsu, Chia‐Chi, Bin-Chi Liao, Wei‐Yu Liao, et al.. (2019). Abstract 4752: Exon-16-skipping HER2 contributes to osimertinib-resistance through Src-independent manner in EGFRL858R/T790M-positive non-small-cell lung cancer. Cancer Research. 79(13_Supplement). 4752–4752. 1 indexed citations

15.

Frigault, Melanie M., Sabina Signoretti, Aleksandra Markovets, et al.. (2018). Abstract 4541: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor. Cancer Research. 78(13_Supplement). 4541–4541. 2 indexed citations

16.

Ahdesmäki, Miika, Brad Chapman, Pablo Cingolani, et al.. (2017). Prioritisation of structural variant calls in cancer genomes. PeerJ. 5. e3166–e3166. 10 indexed citations

17.

Borodovsky, Alexandra, Travis McQuiston, Brian Dougherty, et al.. (2016). Abstract 641: Use of conditional reprogramming to develop and characterize cell cultures from patient-derived xenograft (PDX) models of human lung and ovarian cancer. Cancer Research. 76(14_Supplement). 641–641. 1 indexed citations

18.

Thress, Kenneth S., Cloud P. Paweletz, Enriqueta Felip, et al.. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine. 21(6). 560–562. 1189 indexed citations breakdown →

19.

Asha, Hesarghatta Shyamasunder, István Nagy, Gábor G. Kovács, et al.. (2003). Analysis of Ras-Induced Overproliferation in Drosophila Hemocytes. Genetics. 163(1). 203–215. 250 indexed citations

20.

Dodd, Stephen, Ioannis S. Vrabas, & Daniel Stetson. (1998). Effects of intermittent ischemia on contractile properties and myosin isoforms of skeletal muscle. Medicine & Science in Sports & Exercise. 30(6). 850–855. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact